Capital Investment Advisory Services LLC cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,248 shares of the biopharmaceutical company’s stock after selling 2,204 shares during the quarter. Capital Investment Advisory Services LLC’s holdings in Gilead Sciences were worth $655,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Keel Point LLC raised its holdings in Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 11 shares in the last quarter. West Oak Capital LLC raised its holdings in Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 32 shares in the last quarter. First Heartland Consultants Inc. raised its holdings in Gilead Sciences by 0.4% in the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after purchasing an additional 39 shares in the last quarter. Westover Capital Advisors LLC raised its holdings in Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after purchasing an additional 46 shares in the last quarter. Finally, ARS Investment Partners LLC raised its holdings in Gilead Sciences by 0.9% in the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 50 shares in the last quarter. Institutional investors and hedge funds own 73.99% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at 82.42 on Thursday. The company has a 50-day moving average price of $80.40 and a 200 day moving average price of $71.48. The firm has a market capitalization of $107.63 billion, a P/E ratio of 8.95 and a beta of 1.14. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the previous year, the business earned $3.08 earnings per share. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post $8.78 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a $0.52 dividend. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.52%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at $3,684,920. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 486,819 shares of company stock worth $39,298,919. 1.30% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “Capital Investment Advisory Services LLC Sells 2,204 Shares of Gilead Sciences, Inc. (GILD)” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/capital-investment-advisory-services-llc-sells-2204-shares-of-gilead-sciences-inc-gild/1609063.html.

A number of equities analysts have commented on GILD shares. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price objective on the stock in a report on Wednesday, September 6th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, July 27th. ValuEngine downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 13th. Finally, Bank of America Corporation cut their price objective on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating on the stock in a report on Wednesday. Ten investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $85.36.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.